

1 **Title:** The diagnostic value of plasma phosphorylated tau 181 in Alzheimer's disease  
2 within the Chinese population: A systematic review and meta-analysis

3 **Authors :** Keqiang Yan<sup>1,2,3</sup>, Shuxin He<sup>1,2</sup>, Xiaodong Jia<sup>1,2</sup>, Haiyan Li<sup>1,2</sup>, Dequan  
4 Liu<sup>1,2\*+</sup>, Jianchun Chen<sup>1,2\*+</sup>

5  
6 **Affiliations:**

7 <sup>1</sup>Tianjin Kingmed Diagnostics Laboratory Co.Ltd, Tianjin, China.

8 <sup>2</sup>Tianjin Key Laboratory of Multi-omics Precision Diagnosis Technology for  
9 Neurological Diseases, Tianjin, China.

10 <sup>3</sup>Tianjin Medical University, Tianjin, China

11  
12 <sup>+</sup>Contributed equally

13 <sup>\*</sup>Corresponding author

14 Email: [tianj-liudequan@kingmed.com.cn](mailto:tianj-liudequan@kingmed.com.cn)

15 Address: Building B, Building 3, Sanwu Internet Technology Park, Binhai High-tech  
16 Zone, Tianjin

17  
18 **Abstract**

19 Among all related biomarkers, plasma phosphorylated tau (p-tau181) has  
20 demonstrated strong diagnostic performance in the very early stages of Alzheimer's  
21 disease (AD), showing significant differences between AD patients and healthy  
22 controls. The aim of our present systematic review and meta-analysis was to roundly  
23 evaluate the clinical diagnostic value of plasma p-tau181 based on the Simoa platform  
24 in Chinese populations. We systematically searched five databases (Embase, PubMed,  
25 Cochrane Library, MEDLINE, and Web of Science) from inception to May 11th, 2024,  
26 as well as the references of retrieved relevant articles. We included prospective cohort  
27 studies and retrospective case-control studies in our analysis. Out of 1165 identified  
28 articles, 10 met the inclusion criteria for meta-analysis. Our quantitative analysis  
29 showed that plasma p-tau181 levels were significantly increased in patients with AD  
30 and mild cognitive impairment (MCI) compared to healthy controls (standard mean  
31 difference [SMD]: 1.45 [1.25 - 1.65],  $p < 0.00001$ ; SMD: 0.55 [0.31 - 0.78],  
32  $p < 0.00001$ ) and were lower in MCI patients compared to AD patients (SMD: -0.88  
33 [-0.93 - -0.82],  $p < 0.00001$ ). The reference values for plasma p-tau181 were 4.48  
34 [95% confidence interval (CI): 4.01 - 5.00] for AD patients, 2.86 [95% CI: 2.45 -  
35 3.34] for MCI patients, and 2.09 [95% CI: 1.90 - 2.30] for healthy controls. The  
36 meta-analysis confirmed that plasma p-tau181 significantly increases from healthy  
37 controls to mild cognitive impairment (MCI) and then to AD in the Chinese  
38 population. We also provide reliable reference values for plasma p-tau181, which  
39 contribute to the early diagnosis of AD in Chinese clinical settings.

40 **Keywords:** meta-analysis, p-tau181, Alzheimer's disease

41

## 42 Introduction

43 Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder and a  
44 leading cause of dementia worldwide<sup>[1]</sup>. First identified by Dr. Alois Alzheimer in  
45 1901, AD has since posed significant challenges to the medical community, with no  
46 definitive cure currently available<sup>[2]</sup>. The 2011 National Institute on  
47 Aging-Alzheimer's Association (NIA-AA) Diagnostic Criteria conceptualize AD as a  
48 continuum encompassing three stages: an asymptomatic phase (preclinical AD), a  
49 predementia phase (mild cognitive impairment due to AD), and a dementia phase  
50 (dementia due to AD)<sup>[3-5]</sup>. Pathophysiological changes in AD can commence 15 to 20  
51 years prior to the manifestation of clinical symptoms, underscoring the critical  
52 importance of early diagnosis and timely intervention to potentially slow disease  
53 progression<sup>[6]</sup>.

54 Recent studies have focused on the early detection of AD through the use of fluid  
55 biomarkers<sup>[7]</sup>. Tau proteins, which are microtubule-binding proteins, play an essential  
56 role in maintaining neuronal stability and morphology under normal conditions. The  
57 regional progression of brain atrophy in AD is closely associated with the  
58 accumulation of Tau proteins<sup>[8]</sup>. Hyperphosphorylated Tau (p-tau), in its full-length or  
59 truncated forms, represents a key pathological hallmark of AD, exhibiting over 70  
60 post-translational modifications, including more than 40 phosphorylation sites.  
61 Various forms of p-tau can be measured in cerebrospinal fluid (CSF) and plasma<sup>[9]</sup>.  
62 Among these, p-tau181 is significantly elevated in the CSF of AD patients and is  
63 considered a critical biomarker for the disease<sup>[10]</sup>. The ability of p-tau181 to  
64 differentiate AD from other neurodegenerative conditions, such as frontotemporal  
65 lobar degeneration (FTLD-TDP) and chronic traumatic encephalopathy (CTE), is  
66 crucial for the accurate diagnosis of AD<sup>[11]</sup>. Furthermore, p-tau181 levels correlate  
67 with AD severity and predict disease progression, providing valuable insights for  
68 evaluating therapeutic efficacy and guiding treatment strategies. Recent findings  
69 indicate that p-tau181 have excellent discriminative performance in plasma, paving  
70 the way for non-invasive monitoring of AD<sup>[12-15]</sup>.

71 Advancements in technology, such as the Single-molecule Array (Simoa), have  
72 enabled the detection of plasma p-tau181 at low concentrations<sup>[16]</sup>. The US FDA has  
73 granted breakthrough medical device clearance to this technology, recognizing it as a  
74 valuable tool for diagnosing AD through the detection of p-tau181 biomarkers in  
75 blood<sup>[17-18]</sup>. Currently, this technique is also widely used in the clinical diagnosis of  
76 AD in China. Despite the proven diagnostic value of plasma p-tau181, a large amount  
77 of literature with inconsistent conclusions has confused our understanding of this  
78 field<sup>[19-24]</sup>. There is a notable lack of accurate clinical reference values that can  
79 distinguish AD from healthy elderly individuals. Previous studies, including one by  
80 Ding et al., have attempted to address this by comparing the range of p-tau181  
81 between AD patients and healthy individuals through meta-analysis<sup>[25]</sup>. However,  
82 these studies predominantly collected data from European and American populations,  
83 which may not be applicable to other populations due to quantitative differences in

84 p-tau181 levels among different races and ethnicities. Howell et al. found that older  
85 African Americans had lower CSF levels of p-tau181 compared to older Caucasians,  
86 even after adjusting for demographic variables, genetic factors, and cognitive  
87 function<sup>[26]</sup>. This suggests that there may be race-associated differences in CSF  
88 p-tau181 marker, which also exist in plasma.

89 To address this gap, the primary objective of the present study is to conduct an  
90 extensive and comprehensive meta-analysis to determine the distribution of plasma  
91 p-tau181 levels in both healthy individuals and patients with AD and other  
92 neurodegenerative diseases within the Chinese population. Our aim is to provide more  
93 precise and reliable cut-off thresholds for clinical use, thereby improving the accuracy  
94 of AD and other neurodegenerative disease diagnoses and facilitating early screening  
95 in Chinese clinical settings.

96

## 97 **Methods**

### 98 **Search strategy and study selection**

99 This meta-analysis was conducted in accordance with the Preferred Reporting Items  
100 for a Systematic Review and Meta-analysis (PRISMA) guidelines. The analysis  
101 questions were designed according to the PICOS framework:

- 102 •Participants: clinically diagnosed AD patients;
- 103 •Intervention: evaluation of plasma p-tau181 levels;
- 104 •Comparison: patients clinically diagnosed with non-AD dementia and  
105 cognitively unimpaired participants;
- 106 •Outcome: normal range of plasma p-tau181 levels in healthy Chinese  
107 populations and the efficacy of plasma p-tau181 in differentiating AD from  
108 cognitively unimpaired participants or non-AD dementia patients, based on plasma  
109 p-tau181 level discrepancies;
- 110 •Study design: original, observational cross-sectional and prospective studies.

111 A literature search was conducted across five databases (Embase, PubMed, Cochrane  
112 Library, MEDLINE and Web of Science) on the date of May 11th, 2024, using the  
113 following search terms: plasma phosphorylated tau, Alzheimer disease, AD, Chinese  
114 and Simoa. Candidate studies were included or excluded based on the following  
115 criteria: (1) full text publications written in English; (2) plasma p-tau181 levels  
116 measured using Simoa; (3) Study population consisting of Chinese individuals; (4)  
117 AD diagnosed according to the 2011 and 2018 NIA-AA criteria<sup>[27]</sup> or the 1984  
118 NINCDS-ADRDA criteria<sup>[28]</sup>. Studies were excluded if non-quantitative methods  
119 were employed to assess biomarker levels in the samples.

120

### 121 **Data extraction and quality assessment**

122 Data of interest were independently extracted by two authors (Shuxin He and Keqiang  
123 Yan). Study quality was evaluated using the modified version of the  
124 Newcastle-Ottawa Scale (NOS)<sup>[29]</sup>. A maximum of eight points per study was given  
125 according to the quality of population selection, group comparability and exposure  
126 assessment. Disagreements regarding study selection or data extraction were resolved

127 by additional reviewers (Xiaodong Jia or Haiyan Li).

128

### 129 **Statistical analysis**

130 A random-effects model meta-analysis was employed to calculate the pooled effect  
131 size across multiple studies<sup>[31]</sup>. The normal range of plasma p-tau181 and standardized  
132 mean difference (SMD) between dementia interest groups were represented in forest  
133 plots with 95% confidence intervals (CI)<sup>[31]</sup>. Tau<sup>2</sup> was used to estimate of the  
134 between-study variance in a random-effects meta-analysis. Statistical heterogeneity  
135 across studies was assessed using chi-squared statistic (Chi<sup>2</sup>) and the I<sup>2</sup> index.  
136 According to the Cochrane handbook, I<sup>2</sup> values of 25%, 50%, and 75% represented  
137 low, moderate, and substantial inter-study variability, respectively<sup>[32]</sup>. The Wan et al.  
138 method was employed to estimate the mean and standard deviation (SD) when studies  
139 provided median and interquartile range (IQR)<sup>[33]</sup>. All calculations were conducted  
140 using R statistical software (version 4.3.0).

## 141 **Results**

### 142 **Study inclusions and quality assessment**

143 The search syntax yielded 1165 publications, of which 275 were duplicates and 878  
144 were excluded following abstract screening. Of the 22 entries that were eligible for  
145 full-text assessment, 12 studies were excluded for not complying with the eligibility  
146 criteria: Two studies were not based on a Chinese population; five did not provide  
147 specific diagnostic data for p-tau181; one did not use Simoa assays for measurement;  
148 and four had duplicated published data for the same baseline cohort. Consequently, 10  
149 studies were included in this meta analysis. The detailed selection process is  
150 illustrated by the PRISMA flow diagram in Figure 1. The modified NOS criteria for  
151 quality assessment of the studies indicated that the majority of them were of  
152 high-quality (Table 1). One study scored low on the quality assessment since it only  
153 contained healthy cohort and lacked biomarker diagnosis for inclusion criteria. The  
154 characteristics of the 10 studies, including the number of subjects, average age,  
155 female percentage, and plasma p-tau181 level are presented in Table 2. From the  
156 included studies, 7 studies compared blood biomarkers between AD and healthy  
157 controls (783 AD patients and 508 controls), while four of them also focused on mild  
158 cognitive impairment (MCI) comparing 368 MCI patients and 321 controls. Six  
159 studies paid extra attention to the performance of plasma p-tau181 between 649 AD  
160 patients and 413 non-AD dementia patients (non-ADD), including patients with  
161 cognitive disorders other than AD, such as frontotemporal dementia, vascular  
162 dementia, Lewy body disease, and Parkinson's disease dementia.

163

[Figure 1 here]

### 164 **Plasma p-tau181 levels in healthy cohorts**

165 A summary of plasma p-tau181 levels in Chinese healthy cohorts was presented.  
166 Subgroup analysis was performed according to age and sex ratio. The retrieved data

167 were stratified by mean age into two cohorts: young (< 65 years) and old ( $\geq$  65 years).  
168 The sex ratio was defined as medium (40-60% female) and high (more than 60%  
169 female). Following the removal of one study (Chen J, et al 2023) with high  
170 heterogeneity  $I^2 = 95\%$ , seven studies were included, suggesting that the average  
171 plasma p-tau181 level in Chinese healthy populations was 2.09 pg/ml (95% CI  
172 1.90–2.30,  $I^2 = 77\%$ ,  $P < 0.01$ ) (Figure 2a). The mean plasma p-tau181 levels in  
173 young and old groups were 2.23 pg/ml (95% CI 1.66–3.00) and 2.03 pg/ml (95% CI  
174 1.85–2.30), respectively, with no significant differences observed ( $p = 0.54$ ) (Figure  
175 2b). Nevertheless, there were significant differences ( $p = 0.04$ ) in the subgroup  
176 analyses by sex ratio. As illustrated in Figure 2c, the mean plasma p-tau181  
177 concentration was 1.87 pg/ml (95% CI 1.74-2.01) in the subgroup with more than  
178 60% female participants, in comparison with 2.14 pg/ml (95% CI 1.92-2.37) in the  
179 other subgroup.

180 [Figure 2 here]

### 181 **Plasma p-tau181 levels in AD patients**

182 A total of nine studies with 11 cohorts were conducted to evaluate p-tau181 plasma  
183 levels in 1131 AD patients. The results indicated a mean value of 4.48 pg/ml (95% CI  
184 4.01-5.00,  $I^2 = 93\%$ ,  $P < 0.01$ ) (Figure 3a). The heterogeneity of observed in the data  
185 was influenced by a number of factors, including age and sex composition,  
186 geographic location of the study, time period and the severity of disease. Most of the  
187 studies included in the current analysis employed clinical diagnostic guidelines,  
188 including various iterations of international guidelines, rather than the gold standard  
189 of autopsy-confirmed AD, which may have contributed to the observed heterogeneity.  
190 There was significantly difference of plasma p-tau181 levels between young and old  
191 groups of AD patients ( $P < 0.05$ ), with 4.94 pg/ml (95% CI 4.42–5.53) and 4.12 pg/ml  
192 (95% CI 3.66–4.63) in young and old groups, respectively (Figure 3b). While no  
193 significant differences ( $P = 0.7$ ) in subgroup analysis by sex ratio (Figure 3c).  
194 Subsequently, plasma p-tau181 levels were compared between AD patients and  
195 healthy cohorts. The meta-analysis based on seven studies including 783 AD patients  
196 and 508 control participants, demonstrated that p-tau181 was significantly higher in  
197 AD in comparison to control ( $p < 0.01$ ), providing a SMD of 1.45 (95% CI: 1.25,  
198 1.65), with low heterogeneity ( $I^2 = 33\%$ ) (Figure 3d). In the aspect of differentiating  
199 AD patients from normal controls, three studies demonstrated the diagnostic accuracy  
200 of plasma biomarkers, as indicated by ROC curves. Chen et al. reported as AUC  
201 (Area Under the Curve) of 0.882 (95%CI: 0.79, 0.97) for p-tau181, which was higher  
202 than A $\beta$ 40, A $\beta$ 42 and GAFFP, but was lower than A $\beta$ 42/A $\beta$ 40 (AUC = 0.998, 95%CI:  
203 0.99-1.00). Sun et al. combined plasma markers including A $\beta$ 42/A $\beta$ 40, p-tau181 and  
204 neurofilament light protein (NfL), suggesting the best discriminative performance  
205 (AUC = 0.902) among of all single plasma biomarkers (p-tau181 AUC=0.773), with a  
206 sensitivity and specificity of 0.867 and 0.886, respectively. Wu et al. found that  
207 p-tau181 performed well in both early-onset AD (EOAD) and late-onset AD (LOAD)  
208 patients (AUC = 0.925 and 0.842, respectively) for the AD/control comparison. Three  
209 additional studies focused on the ability of p-tau181 plasma levels in A $\beta$  PET

210 scanning status prediction, with AUC values of 0.813 (Xiao Z, et al., 2023), 0.916  
211 (Guo Y, et al., 2023) and 0.839 (Gao F, et al., 2023 - CANDI cohort). Gao et al.  
212 constructed a logistic regression (LR) model, which combined APOE- $\epsilon$ 4, plasma  
213 p-tau181, and serum glial fibrillary acidic protein (GFAP), resulting in an  
214 improvement in the AUC for distinguishing A $\beta$ -PET status from 0.839 to 0.915.  
215 Subsequently, the efficacy of this LR model was demonstrated in both the CANDI  
216 and multi-center cohorts, showing superior performance compared to any of the blood  
217 biomarkers. Guo et al. found other plasma biomarkers including A $\beta$ 40, A $\beta$ 42,  
218 A $\beta$ 42/A $\beta$ 40 and Nfl, had relatively lower discriminative accuracy than p-tau181.  
219 Furthermore, the study reported that once the CSF A $\beta$ 42/A $\beta$ 40 ratio was positive,  
220 plasma p-tau181 began to increase significantly and continued to increase throughout  
221 the course of preclinical AD.

222 [Figure 3 here]

### 223 **Plasma p-tau181 in MCI patients**

224 Four studies evaluated plasma p-tau181 levels in 368 patients with MCI, suggesting  
225 that the mean value was 2.86 pg/ml (95% CI 2.45–3.34,  $I^2 = 82\%$ ,  $P < 0.01$ ) (Figure  
226 4a). Our further meta-analysis revealed that p-tau181 levels were significantly higher  
227 in MCI patients compared with controls (SMD = 0.55, 95% CI: 0.31, 0.78,  $P < 0.01$ ),  
228 while exhibiting a lower concentration than that in AD patients (SMD = -0.88, 95%  
229 CI: -0.93, -0.82,  $P < 0.01$ ) (Figure 4b, 4c). One study (Wu X, et al. 2021)  
230 demonstrated that p-tau181 exhibited a larger AUC than plasma t-tau, A $\beta$ 40, A $\beta$ 42  
231 and Nfl, achieving an AUC of 0.702 (95% CI: 0.64, 0.764) for the amnesic MCI/Ctrl  
232 comparison and 0.719 (95% CI: 0.661, 0.776) for the amnesic MCI/AD comparison.  
233 The AUC of the amnesic MCI/Ctrl comparison was then improved to 0.789 (95%CI:  
234 0.737, 0.841) through the application of a model comparing t-tau, A $\beta$ 40, A $\beta$ 42,  
235 p-tau181, and NfL, in conjunction age, sex, and education years.

236 [Figure 4 here]

### 237 **Plasma p-tau181 between AD patients and non-AD dementia patients**

238 Five studies with seven cohorts focused on the performance of plasma p-tau181 in  
239 distinguishing AD patients from non-AD dementia patients, demonstrating p-tau181  
240 level was significantly higher in AD. Studies with small sample sizes were not  
241 included in the meta-analysis. Based on the meta-analysis results we proved that the  
242 average p-tau181 level in AD patients was significantly higher than in those non-ADD  
243 patients, providing a SMD of 1.12 (95% CI: 0.53,1.71,  $p < 0.01$ ) (Figure 5). Two  
244 studies reported that p-tau181 had a better performance in discriminating AD from  
245 non-ADD than A $\beta$ 42, A $\beta$ 42/40, GFAP and NfL, providing the AUC of 0.892 and  
246 0.805 respectively<sup>[36-37]</sup>. Besides, the AUC was improved to 0.945 when combined  
247 with other plasma biomarker index (A $\beta$ 42/ A $\beta$ 40, NfL, GFAP) in Chen Y, et al.  
248 research.

249 [Figure 5 here]

## 250 Discussion

251 The current investigation examined the conflicting results of studies on plasma  
252 p-tau181 linked to AD or MCI in the Chinese population, aiming to develop a  
253 non-invasive diagnostic biomarker for the early phases of AD. Plasma p-tau181 levels  
254 may serve as one of the most promising fluid biomarkers for validating AD or MCI  
255 diagnoses. The current findings show that AD is associated with higher blood levels  
256 of p-tau181 compared to MCI and controls. Based on the current literature, we  
257 established the average plasma p-tau181 levels for AD, MCI, and controls in the  
258 Chinese population, providing reference values for future clinical diagnosis.

259 Many meta-analysis studies have demonstrated that plasma p-tau181 can precisely  
260 differentiate AD from MCI and healthy controls. However, most of the studies were  
261 based on Western populations. It is validated that race and ethnicity have impact on  
262 the level of p-tau181 in many studies. Howell et al. found that African Americans  
263 showed lower p-tau181 levels in cerebrospinal fluid (CSF) than Caucasians, which  
264 may lead to underdiagnosis of AD in African Americans<sup>[26]</sup>. Schindler et al. Further  
265 validated that diagnosis performance of plasma p-tau181 in AD is inconsistent  
266 between African (AA) and non-Hispanic White (NHW), which could result in  
267 disproportionate misdiagnosis of AA individuals<sup>[38]</sup>. In the Canadian population, the  
268 reference range for plasma p-tau181 is 0.9-4 pg/ml for individuals aged 60-80. In a  
269 Japanese population study, the interquartile range (IQR) for plasma p-tau181 was  
270 2.58-4.31 pg/ml in PET-positive cohorts, and 1.32-2.33 pg/ml in PET-negative  
271 individuals. Additionally, a meta-analysis by Ding et al. showed that the average  
272 plasma p-tau181 level in the general population is 11.18 pg/ml<sup>[25]</sup>. This is significantly  
273 different from the meta-analysis results for the Chinese population, which reported an  
274 average level of 2.09 pg/ml. This study was conducted among Chinese populations,  
275 which further add to the evidence of plasma p-tau181 as reliable prognostic  
276 candidates for AD and highlight their promising roles in future clinical practice and  
277 research. Cooper et al. found in addition to population, p-tau181 levels are also  
278 affected by other factors such as hypertension, myocardial infarction (MI) and  
279 stroke<sup>[39]</sup>. More comprehensive studies are needed to determine the impact of these  
280 factors on p-tau181 levels.

281 To improve diagnosis accuracy, the p-tau181 was combined with APOE genotyping,  
282 where the presence of an  $\epsilon 4$  allele (encoding the E4 isoform of the apolipoprotein E  
283 protein) is associated with higher probability of AD. Snellman et al. indicates that  
284 plasma p-tau181 levels are significantly higher in APOE4/4 carriers compared to  
285 non-carriers and heterozygous APOE3/4 carriers<sup>[40]</sup>. Elevated levels of plasma  
286 p-tau181 are already observed in cognitively unimpaired high-risk individuals with  
287 homozygous APOE4/4. Cooper et al suggests a strong correlation between p-tau181  
288 levels and APOE  $\epsilon 4$  carrier status in cognitively healthy individuals over 85 years  
289 old<sup>[39]</sup>. Although p-tau181 levels are elevated in elderly APOE  $\epsilon 4$  carriers, their  
290 cognitive abilities remain intact. Combining APOE and p-tau181 markers and  
291 conducting joint analyses may provide more comprehensive predictive information  
292 for clinical diagnosis of Alzheimer's disease.

293 Compared to p-tau181, p-tau217 which is tightly associated with Ab plaque formation  
294 within the brain, suggested a higher specificity to AD. Nevertheless, meta-analysis of  
295 this biomarker could not be done due to too few studies, especially in Chinese  
296 population. Integration of diverse P-tau formed proteins such as p-tau181, p-tau217  
297 and p-tau231 may significantly improved diagnosis power of AD<sup>[41]</sup>.

298

### 299 **Limitations**

300 Some limitations should be addressed in this meta-analysis. Firstly, misdiagnosis  
301 could have occurred in some of the studies included in this systematic review, as  
302 diagnosis was reached mostly on clinical grounds rather than gold-standard  
303 autopsy-confirmed AD. Secondly, only 10 studies were used for meta-analysis, this  
304 small studies can be more heterogeneous than large studies. These findings will be  
305 verified in future large and multicenter cohort studies for subsequent diagnosis for  
306 MCI and AD. Lastly, it is likely that the level of plasma p-tau181 is correlated with  
307 APOE status. However, due to lacking of these data, we can't explore the impact of  
308 APOE to levels of p-tau181 in different groups.

309

### 310 **Conclusion**

311 In summary, our meta-analysis revealed significant relationships of plasma p-tau181  
312 with Alzheimer's patients compared with cognitively normal control subjects and  
313 mild cognitive impairment. The results presented provide preliminary reference value  
314 of plasma p-tau181 for AD and MCI, which may facilitate clinical diagnosis of  
315 neurological diseases for Chinese population.

316 **Funding** All authors acknowledge funding from Tianjin Science and Technology  
317 Leading Cultivation Enterprise Project (22YDPYSY0020).

### 318 **Authors' contributions**

319 KQ Yan conceptualised this systematic review. SX He searched the literature and  
320 screened the titles and abstracts. KQ Yan and SX He reviewed all full-text articles and  
321 extracted data. HY Li and XD Jia formally analysed, visualised and validated the data.  
322 DQ Liu and JC Chen supervised the systematic review. All authors were responsible  
323 for the methodology and review and editing of the manuscript. All authors had final  
324 responsibility for the decision to submit the manuscript for publication.

325



## 326 **References**

- 327 [1]. Prince, M., et al., World Alzheimer Report 2015. The Global Impact of Dementia: An analysis of  
328 prevalence, incidence, cost and trends.. 2015, Alzheimer's Disease International.
- 329 [2]. Tagarelli, A., et al., Alois Alzheimer: a hundred years after the discovery of the eponymous  
330 disorder. *International journal of biomedical science: IJBS*, 2006. 2(2): p. 196.
- 331 [3]. McKhann, G.M., et al., The diagnosis of dementia due to Alzheimer' s disease: Recommendations  
332 from the National Institute on Aging-Alzheimer' s Association workgroups on diagnostic guidelines for  
333 Alzheimer's disease. *Alzheimer's & dementia*, 2011. 7(3): p. 263-269.
- 334 [4]. Albert, M.S., et al., The diagnosis of mild cognitive impairment due to Alzheimer' s disease:  
335 recommendations from the National Institute on Aging-Alzheimer' s Association workgroups on  
336 diagnostic guidelines for Alzheimer' s disease. *Focus*, 2013. 11(1): p. 96-106.
- 337 [5]. Sperling, R.A., et al., Toward defining the preclinical stages of Alzheimer' s disease:  
338 Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on  
339 diagnostic guidelines for Alzheimer's disease. *Alzheimer's & dementia*, 2011. 7(3): p. 280-292.
- 340 [6]. Braak, H. and E. Braak, Neuropathological staging of Alzheimer-related changes. *Acta*  
341 *neuropathologica*, 1991. 82(4): p. 239-259.
- 342 [7]. Chatterjee, P., et al., Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's  
343 disease. *Alzheimer's & Dementia*, 2022. 18(6): p. 1141-1154.
- 344 [8]. Hansson, O., Biomarkers for neurodegenerative diseases. *Nature medicine*, 2021. 27(6): p.  
345 954-963.
- 346 [9]. Mi, K. and G.V. Johnson, The role of tau phosphorylation in the pathogenesis of Alzheimer's  
347 disease. *Current Alzheimer Research*, 2006. 3(5): p. 449-463.
- 348 [10]. Karikari, T.K., et al., Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a  
349 diagnostic performance and prediction modelling study using data from four prospective cohorts. *The*  
350 *Lancet Neurology*, 2020. 19(5): p. 422-433.
- 351 [11]. Thijssen, E.H., et al., Association of Plasma P-tau217 and P-tau181 with clinical phenotype,  
352 neuropathology, and imaging markers in Alzheimer' s disease and frontotemporal lobar degeneration: a  
353 retrospective diagnostic performance study. *The Lancet. Neurology*, 2021. 20(9): p. 739.
- 354 [12]. Thomas, A.J., et al., A longitudinal study of plasma pTau181 in mild cognitive impairment with  
355 Lewy bodies and Alzheimer's disease. *Movement Disorders*, 2022. 37(7): p. 1495-1504.
- 356 [13]. Tissot, C., et al., Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer' s disease.  
357 *Alzheimer's Research & Therapy*, 2021. 13: p. 1-11.
- 358 [14]. Doecke, J.D., et al., Plasma pTau181 and biomarker combinations to identify Alzheimer' s disease  
359 at any stage along the AD continuum compared with both controls and non - AD dementia.  
360 *Alzheimer's & Dementia*, 2023. 19: p. e077504.
- 361 [15]. Coomans, E.M., et al., A head-to-head comparison between plasma ptau181 and tau pet along the  
362 Alzheimer' s disease continuum. *Journal of Nuclear Medicine*, 2023. 64(3): p. 437-443.
- 363 [16]. Rissin, D.M., et al., Single-molecule enzyme-linked immunosorbent assay detects serum proteins  
364 at subfemtomolar concentrations. *Nature biotechnology*, 2010. 28(6): p. 595-599.
- 365 [17]. Janelidze, S., et al., Plasma P-tau181 in Alzheimer' s disease: relationship to other biomarkers,  
366 differential diagnosis, neuropathology and longitudinal progression to Alzheimer' s dementia. *Nature*  
367 *medicine*, 2020. 26(3): p. 379-386.
- 368 [18]. Karikari, T.K., et al., Diagnostic performance and prediction of clinical progression of plasma

- 369 phospho-tau181 in the Alzheimer ' s Disease Neuroimaging Initiative. *Molecular psychiatry*, 2021.  
370 26(2): p. 429-442.
- 371 [19]. Chen, J., et al., Reference intervals for plasma amyloid-  $\beta$  , total tau, and phosphorylated tau181 in  
372 healthy elderly Chinese individuals without cognitive impairment. *Alzheimer's Research & Therapy*,  
373 2023. 15(1): p. 100.
- 374 [20]. Guo, Y., et al., The dynamics of plasma biomarkers across the Alzheimer ' s continuum.  
375 *Alzheimer's Research & Therapy*, 2023. 15(1): p. 31.
- 376 [21]. Sun, Q., et al., Plasma  $\beta$  -amyloid, tau, neurodegeneration biomarkers and inflammatory factors  
377 of probable Alzheimer ' s disease dementia in Chinese individuals. *Frontiers in Aging Neuroscience*,  
378 2022. 14: p. 963845.
- 379 [22]. Cai, H., et al., Plasma biomarkers predict Alzheimer ' s disease before clinical onset in Chinese  
380 cohorts. *Nature Communications*, 2023. 14(1): p. 6747.
- 381 [23]. Wu, X., et al., Development of a plasma biomarker diagnostic model incorporating ultrasensitive  
382 digital immunoassay as a screening strategy for Alzheimer disease in a Chinese population. *Clinical*  
383 *Chemistry*, 2021. 67(12): p. 1628-1639.
- 384 [24]. Gao, F., et al., Blood-based biomarkers for Alzheimer ' s disease: a multicenter-based  
385 cross-sectional and longitudinal study in China. *Science Bulletin*, 2023. 68(16): p. 1800-1808.
- 386 [25]. Ding, X., et al., Ultrasensitive assays for detection of plasma tau and phosphorylated tau 181 in  
387 Alzheimer ' s disease: a systematic review and meta-analysis. *Translational neurodegeneration*, 2021. 10:  
388 p. 1-14.
- 389 [26]. Howell, J.C., et al., Race modifies the relationship between cognition and Alzheimer ' s disease  
390 cerebrospinal fluid biomarkers. *Alzheimer's research & therapy*, 2017. 9: p. 1-10.
- 391 [27]. Jack Jr, C.R., et al., NIA-AA research framework: toward a biological definition of Alzheimer's  
392 disease. *Alzheimer's & dementia*, 2018. 14(4): p. 535-562.
- 393 [28]. McKhann, G., et al., Clinical diagnosis of Alzheimer's disease: Report of the NINCDS - ADRDA  
394 Work Group\* under the auspices of Department of Health and Human Services Task Force on  
395 Alzheimer's Disease. *Neurology*, 1984. 34(7): p. 939-939.
- 396 [29]. Wells, G.A., et al., The Newcastle-Ottawa Scale (NOS) for assessing the quality of  
397 nonrandomised studies in meta-analyses. 2000.
- 398 [30]. Van Houwelingen, H.C., L.R. Arends and T. Stijnen, Advanced methods in meta - analysis:  
399 multivariate approach and meta - regression. *Statistics in medicine*, 2002. 21(4): p. 589-624.
- 400 [31]. Friedrich, J.O., N.K. Adhikari and J. Beyene, The ratio of means method as an alternative to mean  
401 differences for analyzing continuous outcome variables in meta-analysis: a simulation study. *BMC*  
402 *Medical Research Methodology*, 2008. 8: p. 1-15.
- 403 [32]. Higgins, J.P., et al., Measuring inconsistency in meta-analyses. *Bmj*, 2003. 327(7414): p. 557-560.
- 404 [33]. Wan, X., et al., Estimating the sample mean and standard deviation from the sample size, median,  
405 range and/or interquartile range. *BMC medical research methodology*, 2014. 14: p. 1-13.
- 406 [34]. Chen, Y., et al., Diagnostic value of isolated plasma biomarkers and its combination in  
407 neurodegenerative dementias: A multicenter cohort study. *Clinica Chimica Acta*, 2024. 558: p. 118784.
- 408 [35]. Huang, L., et al., Neuropsychiatric symptoms in Alzheimer's continuum and their association with  
409 plasma biomarkers. *Journal of Affective Disorders*, 2024. 348: p. 200-206.
- 410 [36]. Shang, L., et al., Association of APOE  $\epsilon$  4/  $\epsilon$  4 with fluid biomarkers in patients from the  
411 PUMCH dementia cohort. *Frontiers in Aging Neuroscience*, 2023. 15: p. 1119070.
- 412 [37]. Xiao, Z., et al., Plasma p - tau217, p - tau181, and NfL as early indicators of dementia risk in a

413 community cohort: The Shanghai Aging Study. *Alzheimer's & Dementia: Diagnosis, Assessment &*  
414 *Disease Monitoring*, 2023. 15(4): p. e12514.  
415 [38]. Schindler, S.E., et al., Effect of race on prediction of brain amyloidosis by plasma A  $\beta$  42/A  $\beta$  40,  
416 phosphorylated tau, and neurofilament light. *Neurology*, 2022. 99(3): p. e245-e257.  
417 [39]. Mielke, M.M., et al., Performance of plasma phosphorylated tau 181 and 217 in the community.  
418 *Nature medicine*, 2022. 28(7): p. 1398-1405.  
419 [40]. Cooper, J.G., et al., APOE  $\epsilon$  4 carrier status modifies plasma p - tau181 concentrations in  
420 cognitively healthy super - seniors. *Alzheimer's & Dementia*, 2024.  
421 [41]. Qu, Y., et al., Blood biomarkers for the diagnosis of amnesic mild cognitive impairment and  
422 Alzheimer' s disease: A systematic review and meta-analysis. *Neuroscience & Biobehavioral Reviews*,  
423 2021. 128: p. 479-486.

424

425

426

427 Table 1. Quality assessment of included studies in the meta-analysis using NEWCASTLE -  
428 OTTAWA QUALITY ASSESSMENT SCALE (NOS)

	Selection				Comparability	Exposure		
	Is the case definition adequate?	Representativeness of the cases	Selection of Controls	Definition of Controls		Comparability of cases and controls on the basis of the design or analysis	Ascertainment of exposure	Same method of ascertainment for cases and controls
Chen J, et al. 2023	NA	NA	-	-	NA	*	NA	*
Guo Y, et al. 2023	*	*	*	*	**	*	*	*
Sun Q, et al. 2022	*	*	*	*	*	*	*	*
Cai H, et al. 2023	*	*	*	*	*	*	*	*
Wu X, et al. 2021	-	*	*	*	*	*	*	*
Gao F, et al. 2023	*	*	*	*	*	*	*	*
Chen Y, et al. 2024	*	*	*	*	*	*	*	*
Huang L, et al. 2024	*	*	*	*	**	*	*	*
Shang L, et al. 2023	*	*	*	*	*	*	*	*
Xiao Z, et al. 2023	-	*	*	*	*	*	*	*

429

430

431 Table 2. Basic characteristics of included studies for plasma p-tau181 analysis

432

Study	Subjects (n)	Female (%)	Age (years)	P-tau181 (pg/ml)
Chen J, et al. 2023 <sup>[19]</sup>	CN (193)	49.7	67.3 ± 9.8	1.19 (0.88, 1.76)
	CN (43)	58.82	57.02 ± 6.76	1.92 ± 0.78
Guo Y, et al. 2023 <sup>[20]</sup>	MCI (36)	58.33	66.72 ± 9.82	2.88 ± 1.70
	AD (93)	59.14	59.48 ± 8.28	4.60 ± 1.82
	Non-AD dementia (68)	41.18	62.41 ± 8.70	2.08 ± 1.16
Sun Q, et al. 2022 <sup>[21]</sup>	CN (44)	50	71.86 ± 7.76	2.27 (1.78, 3.18)
	AD (30)	40	75.27 ± 7.67	3.94 (3.02, 5.39)
Cai H, et al. 2023 <sup>[22]</sup>	CN (123)	50.4	70.0 ± 7.1	1.9 (1.51, 2.67)
	AD (126)	50	69.0 ± 6.3	3.97 ± 1.39
	CN (121)	62.8	69.3 ± 7.1	1.8 (1.4, 2.4)
Wu X, et al. 2021 <sup>[23]</sup>	MCI (148)	54.1	69.7 ± 8.8	4.3 (3.0, 5.6)
	AD (159)	57.2	66.9 ± 9.9	2.6 (1.7, 3.9)
	CN (104)	52.9	59.1 ± 8.6	2.6 ± 1.8
Gao F, et al. 2023 - CANDI cohort <sup>[24]</sup>	MCI (110)	62.7	63.3 ± 9.3	3.5 ± 2.3
	AD (208)	63.9	63.0 ± 8.1	5.8 ± 2.8
	Non-AD dementia (55)	49.1	61.9 ± 8.1	3.5 ± 2.8
Gao F, et al. 2023 - WCH cohort <sup>[24]</sup>	AD (47)	57.4	76.8 ± 6.0	5.8 ± 3.0
	Non-AD dementia (81)	58.0	60.9 ± 7.4	2.9 ± 1.0
Gao F, et al. 2023 - SAHZU cohort <sup>[24]</sup>	AD (36)	66.7	61.9 ± 9.6	4.1 ± 1.6
	Non-AD dementia (19)	31.6	60.4 ± 9.8	3.5 ± 1.9
	CN (20)	50	65.7 ± 9.1	1.8 (1.4, 2.8)
Chen Y, et al. 2024 <sup>[34]</sup>	AD (64)	48.44	62.8 ± 10.7	5.2 (3.8, 7.1)
	FTD (16)	62.5	64.3 ± 9.0	2.9 (2.2, 5.0)
	PSP (12)	58.33	71.8 ± 5.9	2.9 (1.5, 3.2)
	CN (53)	45.28	65.13 ± 6.96	1.93 ± 0.90
Huang L, et al. 2024 <sup>[35]</sup>	MCI (74)	48.65	65.72 ± 6.60	2.43 ± 1.44
	AD (103)	59.22	66.03 ± 8.21	3.95 ± 1.94

<b>Study</b>	<b>Subjects (n)</b>	<b>Female (%)</b>	<b>Age (years)</b>	<b>P-tau181 (pg/ml)</b>
Shang L, et al. 2023 <sup>[36]</sup>	AD (120)	55.8	60.8 ± 7.9	4.9 ± 1.9
	Non-AD dementia (128)	46.9	61.7 ± 9.1	2.7 ± 1.4
Xiao Z, et al. 2023 <sup>[37]</sup>	AD (145)	62.1	79.1 ± 6.1	3.12 ± 2.30
	Non-AD dementia (62)	71	77.8 ± 5.9	2.22 ± 0.80

433


434

435 **Figures**

436


437 Figure 1. PRISMA flow diagram of study selection process

438




439

440 Figure 2. Forest plot of random effects meta-analysis of plasma p-tau181 levels in  
441 healthy controls (A), age subgroups (B) and sex ratio subgroups (C).



442

443 Figure 3. Forest plot of random effects meta-analysis of plasma p-tau181 levels in AD  
 444 patients (A), age subgroups (B) and sex ratio subgroups (C). Meta-analysis of studies  
 445 comparing p-tau181 levels between AD and healthy controls (D).




446

447 Figure 4. Forest plot of random effects meta-analysis of plasma p-tau181 levels in  
448 MCI patients (A), age subgroups (B) and sex ratio subgroups (C).

449






450

451 Figure 5. Forest plot of random effects meta-analysis of plasma p-tau181 levels in AD  
452 and non-AD patients.

453



454

455

456